CL2012002542A1 - Proceso in vitro para la determinación rápida del estado de infección de pacientes con infección por mycobacterium tuberculosis a partir de sangre entera en términos de tuberculosis activa o latente, que comprende las etapas de (i) estimular una célula t antígeno específico, y (ii) determinar un perfil de citosinas a partir de tanto la producción intracelular de inf-gamma como de il-2. - Google Patents

Proceso in vitro para la determinación rápida del estado de infección de pacientes con infección por mycobacterium tuberculosis a partir de sangre entera en términos de tuberculosis activa o latente, que comprende las etapas de (i) estimular una célula t antígeno específico, y (ii) determinar un perfil de citosinas a partir de tanto la producción intracelular de inf-gamma como de il-2.

Info

Publication number
CL2012002542A1
CL2012002542A1 CL2012002542A CL2012002542A CL2012002542A1 CL 2012002542 A1 CL2012002542 A1 CL 2012002542A1 CL 2012002542 A CL2012002542 A CL 2012002542A CL 2012002542 A CL2012002542 A CL 2012002542A CL 2012002542 A1 CL2012002542 A1 CL 2012002542A1
Authority
CL
Chile
Prior art keywords
infection
cytosine
stimulating
gamma
patients
Prior art date
Application number
CL2012002542A
Other languages
English (en)
Inventor
Ferdinand Hermann Bahlmann
Danilo Fliser
Martina Sester
Urban Sester
Original Assignee
Red Flag Diagnostics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Red Flag Diagnostics Gmbh filed Critical Red Flag Diagnostics Gmbh
Publication of CL2012002542A1 publication Critical patent/CL2012002542A1/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/5695—Mycobacteria
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6866—Interferon
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/54—Interleukins [IL]
    • G01N2333/55—IL-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Proceso in vitro para la determinación rápida del estado de infección de pacientes con infección por Mycobacterium Tuberculosis a partir de sangre entera en términos de tuberculosis activa o latente, que comprende las etapas de (I) estimular una célula T antígeno específico, y (II) determinar un perfil de citosinas a partir de tanto la producción intracelular de INF-gamma como de il-2.
CL2012002542A 2010-03-19 2012-09-13 Proceso in vitro para la determinación rápida del estado de infección de pacientes con infección por mycobacterium tuberculosis a partir de sangre entera en términos de tuberculosis activa o latente, que comprende las etapas de (i) estimular una célula t antígeno específico, y (ii) determinar un perfil de citosinas a partir de tanto la producción intracelular de inf-gamma como de il-2. CL2012002542A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28270110P 2010-03-19 2010-03-19
EP10157086 2010-03-19

Publications (1)

Publication Number Publication Date
CL2012002542A1 true CL2012002542A1 (es) 2013-02-08

Family

ID=42457988

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012002542A CL2012002542A1 (es) 2010-03-19 2012-09-13 Proceso in vitro para la determinación rápida del estado de infección de pacientes con infección por mycobacterium tuberculosis a partir de sangre entera en términos de tuberculosis activa o latente, que comprende las etapas de (i) estimular una célula t antígeno específico, y (ii) determinar un perfil de citosinas a partir de tanto la producción intracelular de inf-gamma como de il-2.

Country Status (16)

Country Link
US (2) US20130122523A1 (es)
EP (1) EP2548019A1 (es)
JP (1) JP5925184B2 (es)
KR (1) KR20130029063A (es)
AU (1) AU2011228996B2 (es)
BR (1) BR112012023678A2 (es)
CA (1) CA2793151C (es)
CL (1) CL2012002542A1 (es)
CO (1) CO6640286A2 (es)
CU (1) CU20120141A7 (es)
MD (1) MD20120084A2 (es)
MX (1) MX2012010720A (es)
RU (1) RU2012144417A (es)
SG (1) SG184103A1 (es)
WO (1) WO2011113953A1 (es)
ZA (1) ZA201206950B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2655662A2 (en) 2010-12-23 2013-10-30 Centre Hospitalier Universitaire Vaudois Lausanne (CHUV) Methods for differentiating between disease states
WO2012167307A1 (en) * 2011-06-06 2012-12-13 The University Of Melbourne Diagnosis of mycobacterial infection
WO2013106338A1 (en) 2012-01-12 2013-07-18 Mayo Foundation For Medical Education And Research Detecting latent tuberculosis infections
US10401360B2 (en) 2013-04-29 2019-09-03 Mayo Foundation For Medical Education And Research Flow cytometry assay methods
GB201315748D0 (en) 2013-09-04 2013-10-16 Imp Innovations Ltd Biological methods and materials for use therein
US9549914B2 (en) 2014-04-03 2017-01-24 The Johns Hopkins University Treatment of human cytomegalovirus by modulating Wnt
JP6306124B2 (ja) * 2016-11-01 2018-04-04 国立大学法人高知大学 結核検査用バイオマーカー
EP3555630B1 (en) 2016-12-14 2023-05-31 Becton, Dickinson and Company Methods and compositions for obtaining a tuberculosis assessment in a subject
CN107831316A (zh) * 2017-10-31 2018-03-23 扬州大学 一种用于诊断牛结核病的流式细胞术检测试剂盒
CN109777852A (zh) * 2019-01-29 2019-05-21 浙江省人民医院 特异性抗原刺激cd4淋巴细胞表达cd69用于诊断结核杆菌感染的方法
KR102326294B1 (ko) * 2019-10-27 2021-11-16 바디텍메드(주) 결핵 진단 장치

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7514232B2 (en) 1996-12-06 2009-04-07 Becton, Dickinson And Company Method for detecting T cell response to specific antigens in whole blood
WO2002054072A2 (en) * 2001-01-08 2002-07-11 Isis Innovation Limited Assay to determine efficacy of treatment for mycobacterial infection
WO2006069460A2 (de) * 2004-12-30 2006-07-06 Medmix Systems Ag Mehrkomponenten-austragvorrichtung für flüssige und pulverförmige stoffe
EA012436B1 (ru) * 2005-01-05 2009-10-30 Айсис Инновейшн Лимитед Композиции для иммунизации против микобактерий
EP1767937A1 (en) * 2005-09-27 2007-03-28 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method of diagnosis of tuberculosis related immune restoration syndrome (IRS)
GB0605474D0 (en) * 2006-03-17 2006-04-26 Isis Innovation Clinical correlates
ES2558543T3 (es) 2007-03-16 2016-02-05 Cellestis Limited Un ensayo de respuesta inmunitaria mediada por células y kits para el mismo

Also Published As

Publication number Publication date
US20130122523A1 (en) 2013-05-16
AU2011228996B2 (en) 2015-01-29
US20150099652A1 (en) 2015-04-09
CA2793151A1 (en) 2011-09-22
RU2012144417A (ru) 2014-04-27
CU20120141A7 (es) 2013-01-30
AU2011228996A1 (en) 2012-10-11
CO6640286A2 (es) 2013-03-22
MD20120084A2 (ro) 2013-04-30
US9476877B2 (en) 2016-10-25
ZA201206950B (en) 2013-05-29
WO2011113953A1 (en) 2011-09-22
JP5925184B2 (ja) 2016-05-25
SG184103A1 (en) 2012-10-30
KR20130029063A (ko) 2013-03-21
CA2793151C (en) 2018-05-22
JP2013522637A (ja) 2013-06-13
BR112012023678A2 (pt) 2016-08-23
EP2548019A1 (en) 2013-01-23
MX2012010720A (es) 2013-01-29

Similar Documents

Publication Publication Date Title
CL2012002542A1 (es) Proceso in vitro para la determinación rápida del estado de infección de pacientes con infección por mycobacterium tuberculosis a partir de sangre entera en términos de tuberculosis activa o latente, que comprende las etapas de (i) estimular una célula t antígeno específico, y (ii) determinar un perfil de citosinas a partir de tanto la producción intracelular de inf-gamma como de il-2.
BR112013003160A2 (pt) tratamento de diabetes com células precursoras endócrinas pancráticas
AR080570A1 (es) Metodo para distinguir infecciones de mycobacterium tuberculosis activas versus latentes
AR051524A1 (es) Seleccion de pacientes para una terapia con un inhibidor de her
WO2011138786A3 (en) Stem cell bank for personalized medicine
CY1120115T1 (el) Προερχομενα απο μυελο των οστων μεσεγχυματικα αρχεγονα κυτταρα ως μια πηγη νευρικων προγονων
EP4309580A3 (en) Continuous analyte measurement system
CY1120800T1 (el) Μεθοδοι και συνθεσεις για την in vivo ενεργοποιηση του σχηματισμου παγκρεατικων βητα κυτταρων
UY33748A (es) Anticuerpos humanos contra el receptor del glucagón
BR112013000822A2 (pt) método e método de duas etapas para a produção de uma população de células exterminadoras naturais (nk) ativadas, população de células nk ativadas e método para suprimir a proliferação de células tumorais
BR112014028881A2 (pt) populações de células, banco de células, métodos de obtenção de uma população de células, métodos de identificação de um fator, métodos de seleção, métodos de fornecimento de terapia, populações de hepatócitos e método de obtenção de células
ES2422739T3 (es) Composición para el diagnóstico, prevención o tratamiento de enfermedades relacionadas con células que expresan IL-8 o GRO-, que comprende MSC de UCB
EP4306636A3 (en) Monolayer of pbmcs or bone-marrow cells and uses thereof
EA036698B9 (ru) Моноклональное антитело против lif человека и его применение для лечения рака с высоким уровнем lif
MX2015014892A (es) Metodo para un ensayo de deteccion de farmacos basado en celulas y el uso del mismo.
ATE520032T1 (de) Differentielle cytokinexpression bei einer menschlichen krebserkrankung
BR112018004454A2 (pt) nova subpopulação de tregs cd8+cd45rcbaixo e seu uso
CY1121973T1 (el) Θεραπεια φαρμακευτικα ανθεκτικου καρκινου η οποια στοχευει καρκινικα βλαστοκυτταρα
AR084263A1 (es) Anticuerpo dirigido contra una proteina de membrana de celulas dendriticas (bdca-2) (blood dendritic cell antigen)
CL2008003282A1 (es) Poblacion de celulas humanas que expresan cd34 las cuales son obtenidas a partir de expansion de celulas de sangre de cordon umbilical en presencia de celulas menstruales humanas, metodo para obtener dichas celulas.
ES2479543T1 (es) Poblaciones celulares que tienen actividad inmunorreguladora, métodos para la preparación y usos de las mismas
GB2520889A (en) Patient reported outcome instrument
BR112012004689A2 (pt) métodos para extração e purificação de gangliosídeos.
MY179888A (en) Autologous tissue-engineered human skin construct and a method for producing thereof
UY31522A1 (es) Nanoparticulas con superficie modificada